PL1633390T3 - Stabilizowane kompozycje farmaceutyczne peptydu glp-1 - Google Patents

Stabilizowane kompozycje farmaceutyczne peptydu glp-1

Info

Publication number
PL1633390T3
PL1633390T3 PL04735870T PL04735870T PL1633390T3 PL 1633390 T3 PL1633390 T3 PL 1633390T3 PL 04735870 T PL04735870 T PL 04735870T PL 04735870 T PL04735870 T PL 04735870T PL 1633390 T3 PL1633390 T3 PL 1633390T3
Authority
PL
Poland
Prior art keywords
glp
peptide compositions
stabilized pharmaceutical
stabilized
pharmaceutical
Prior art date
Application number
PL04735870T
Other languages
English (en)
Inventor
Claus Juul-Mortensen
Dorte Kot Engelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL1633390T3 publication Critical patent/PL1633390T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL04735870T 2003-06-03 2004-06-03 Stabilizowane kompozycje farmaceutyczne peptydu glp-1 PL1633390T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200300819 2003-06-03
US47627903P 2003-06-05 2003-06-05
DKPA200400075 2004-01-19
US53852504P 2004-01-22 2004-01-22
PCT/DK2004/000380 WO2004105781A2 (en) 2003-06-03 2004-06-03 Stabilized pharmaceutical peptide compositions
EP04735870A EP1633390B1 (en) 2003-06-03 2004-06-03 Stabilized pharmaceutical glp-1 peptide compositions

Publications (1)

Publication Number Publication Date
PL1633390T3 true PL1633390T3 (pl) 2012-06-29

Family

ID=33494167

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04735870T PL1633390T3 (pl) 2003-06-03 2004-06-03 Stabilizowane kompozycje farmaceutyczne peptydu glp-1

Country Status (7)

Country Link
EP (1) EP1633390B1 (pl)
KR (1) KR101293507B1 (pl)
AU (1) AU2004243531B2 (pl)
CA (1) CA2527743A1 (pl)
MX (1) MXPA05013048A (pl)
PL (1) PL1633390T3 (pl)
WO (1) WO2004105781A2 (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
EP1789434B1 (en) 2004-08-31 2013-11-20 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
EP1817048B1 (en) 2004-11-12 2014-02-12 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
AU2008205229B2 (en) * 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
AU2012213435B2 (en) * 2011-02-02 2017-03-30 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
CN104662038B (zh) * 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
CA2916222C (en) 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
WO2020127476A1 (en) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations
WO2022157747A2 (en) * 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525371A (ja) * 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ES2249933T3 (es) * 1998-12-22 2006-04-01 Eli Lilly And Company Formulacion autoestable de peptido 1 tipo glucagon.
US7199217B2 (en) * 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
DK1412384T3 (da) * 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
MXPA04001560A (es) * 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.

Also Published As

Publication number Publication date
EP1633390B1 (en) 2012-01-18
AU2004243531A1 (en) 2004-12-09
MXPA05013048A (es) 2006-03-02
AU2004243531B2 (en) 2009-11-05
WO2004105781A2 (en) 2004-12-09
EP1633390A2 (en) 2006-03-15
WO2004105781A3 (en) 2005-03-17
KR20060017531A (ko) 2006-02-23
CA2527743A1 (en) 2004-12-09
KR101293507B1 (ko) 2013-08-06

Similar Documents

Publication Publication Date Title
PL1633390T3 (pl) Stabilizowane kompozycje farmaceutyczne peptydu glp-1
PL1633391T3 (pl) Stabilizowane farmaceutycznie kompozycje peptydowe
GB2389530B (en) Pharmaceutical compositions
AU2003302603A8 (en) Improved opioid pharmaceutical compositions
GB0320382D0 (en) Pharmaceutical compositions
GB0327723D0 (en) Pharmaceutical compositions
AU2003291103A8 (en) Pharmaceutical composition
IL164547A0 (en) Pharmaceutical composition
EP1694278A4 (en) GLP-1 PHARMACEUTICAL COMPOSITIONS
GB2391473B (en) Pharmaceutical compositions
IL165878A0 (en) Pharmaceutical composition
GB0300531D0 (en) Pharmaceutical compositions
EP1648411A4 (en) PHARMACEUTICAL COMPOSITIONS
PL380482A1 (pl) Farmaceutyczne kompozycje
GB0213481D0 (en) Pharmaceutical compositions
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
HK1065477A1 (en) Pharmaceutical composition
GB0305579D0 (en) Pharmaceutical compositions
HU0200337D0 (en) Stabilised pharmaceutical composition
PL370907A1 (pl) Kompozycje farmaceutyczne
GB0217703D0 (en) Pharmaceutical composition
GB0327389D0 (en) Stabilised pharmaceutical compositions
GB0221068D0 (en) Pharmaceutical compositions
GB0225880D0 (en) Pharmaceutical compositions
GB0209379D0 (en) Pharmaceutical compositions